Challenges and New Directions in Therapeutic Cancer Vaccine Development

Overview

Journal Vaccines (Basel)

Date 2025 Jan 8

PMID 39772003

Authors

Danjie Pan

Jiayang Liu

Xuan Huang

Songna Wang

Kudelaidi Kuerban

Yan Yan

Yi Zhun Zhu

Li Ye

Affiliations

Soon will be listed here.

Abstract

Tumor vaccine is a promising immunotherapy for solid tumors. Therapeutic tumor vaccines aim at inducing tumor regression, establishing durable antitumor memory, and avoiding non-specific or adverse reactions. However, tumor-induced immune suppression and immune resistance pose challenges to achieving this goal. In this article, we review multiple challenges currently faced in the development of therapeutic tumor vaccines, with a particular focus on anonymous antigen vaccines in situ as a new direction. We summarize the research progress in this area, aiming to provide a reference for future studies on tumor vaccines.

References

Zhao X, Subramanian S . Intrinsic Resistance of Solid Tumors to Immune Checkpoint Blockade Therapy. Cancer Res. 2017; 77(4):817-822. DOI: 10.1158/0008-5472.CAN-16-2379. View

Von Rueden S, Fan T . Cancer-Immunity Cycle and Therapeutic Interventions- Opportunities for Including Pet Dogs With Cancer. Front Oncol. 2021; 11:773420. PMC: 8639699. DOI: 10.3389/fonc.2021.773420. View

Taube J, Klein A, Brahmer J, Xu H, Pan X, Kim J . Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014; 20(19):5064-74. PMC: 4185001. DOI: 10.1158/1078-0432.CCR-13-3271. View

Khong H, Overwijk W . Adjuvants for peptide-based cancer vaccines. J Immunother Cancer. 2016; 4:56. PMC: 5028954. DOI: 10.1186/s40425-016-0160-y. View

Lam H, McNeil L, Starobinets H, DeVault V, Cohen R, Twardowski P . An Empirical Antigen Selection Method Identifies Neoantigens That Either Elicit Broad Antitumor T-cell Responses or Drive Tumor Growth. Cancer Discov. 2021; 11(3):696-713. DOI: 10.1158/2159-8290.CD-20-0377. View

Cheng H, Chen W, Lin Y, Zhang J, Song X, Zhang D . Signaling pathways involved in the biological functions of dendritic cells and their implications for disease treatment. Mol Biomed. 2023; 4(1):15. PMC: 10183318. DOI: 10.1186/s43556-023-00125-3. View

Peng M, Mo Y, Wang Y, Wu P, Zhang Y, Xiong F . Neoantigen vaccine: an emerging tumor immunotherapy. Mol Cancer. 2019; 18(1):128. PMC: 6708248. DOI: 10.1186/s12943-019-1055-6. View

Qi X, Zhang F, Wu H, Liu J, Zong B, Xu C . Wilms' tumor 1 (WT1) expression and prognosis in solid cancer patients: a systematic review and meta-analysis. Sci Rep. 2015; 5:8924. PMC: 4352850. DOI: 10.1038/srep08924. View

Galluzzi L, Vitale I, Warren S, Adjemian S, Agostinis P, Buque Martinez A . Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. J Immunother Cancer. 2020; 8(1). PMC: 7064135. DOI: 10.1136/jitc-2019-000337. View

10.

Liu S, Jiang Q, Zhao X, Zhao R, Wang Y, Wang Y . A DNA nanodevice-based vaccine for cancer immunotherapy. Nat Mater. 2020; 20(3):421-430. DOI: 10.1038/s41563-020-0793-6. View

11.

Amos S, Pegram H, Westwood J, John L, Devaud C, Clarke C . Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in mice. Cancer Immunol Immunother. 2011; 60(5):671-83. PMC: 3499620. DOI: 10.1007/s00262-011-0984-8. View

12.

Dhandapani H, Seetharaman A, Jayakumar H, Ganeshrajah S, Sunder Singh S, Thangarajan R . Autologous cervical tumor lysate pulsed dendritic cell stimulation followed by cisplatin treatment abrogates FOXP3+ cells in vitro. J Gynecol Oncol. 2021; 32(4):e59. PMC: 8192235. DOI: 10.3802/jgo.2021.32.e59. View

13.

Andtbacka R, Kaufman H, Collichio F, Amatruda T, Senzer N, Chesney J . Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. J Clin Oncol. 2015; 33(25):2780-8. DOI: 10.1200/JCO.2014.58.3377. View

14.

Shalhout S, Miller D, Emerick K, Kaufman H . Therapy with oncolytic viruses: progress and challenges. Nat Rev Clin Oncol. 2023; 20(3):160-177. DOI: 10.1038/s41571-022-00719-w. View

15.

Lin Z, Meng X, Wen J, Corral J, Andreev D, Kachler K . Intratumor Heterogeneity Correlates With Reduced Immune Activity and Worse Survival in Melanoma Patients. Front Oncol. 2020; 10:596493. PMC: 7747763. DOI: 10.3389/fonc.2020.596493. View

16.

Zhu X, Nishimura F, Sasaki K, Fujita M, Dusak J, Eguchi J . Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models. J Transl Med. 2007; 5:10. PMC: 1802742. DOI: 10.1186/1479-5876-5-10. View

17.

Ebrahimi-Nik H, Moussa M, Englander R, Singhaviranon S, Michaux J, Pak H . Reversion analysis reveals the in vivo immunogenicity of a poorly MHC I-binding cancer neoepitope. Nat Commun. 2021; 12(1):6423. PMC: 8571378. DOI: 10.1038/s41467-021-26646-5. View

18.

Janes M, Gottlieb A, Park K, Zhao Z, Mitragotri S . Cancer vaccines in the clinic. Bioeng Transl Med. 2024; 9(1):e10588. PMC: 10771564. DOI: 10.1002/btm2.10588. View

19.

Cueto F, Sancho D . The Flt3L/Flt3 Axis in Dendritic Cell Biology and Cancer Immunotherapy. Cancers (Basel). 2021; 13(7). PMC: 8037622. DOI: 10.3390/cancers13071525. View

20.

Hodi F, ODay S, Mcdermott D, Weber R, Sosman J, Haanen J . Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363(8):711-23. PMC: 3549297. DOI: 10.1056/NEJMoa1003466. View